tuberculosis H37Rv chromosomal DNA template with the primers Ag85

tuberculosis H37Rv chromosomal DNA template with the primers Ag85BF, 5′-AATGGATCCTTCTCCCGGCCGGGGCT-3′(BamHI), and HspXF1, 5′- ATAGAGCTCATGGCCACACCCTTC-3′(SacI), as forward primers and the primers Ag85BR, 5′-ATTGAGCTCGCCGGCGCCTAACGAACTCTGGAG-3′(SacI), and HspXR, 5′-ACGAAGCTTTCAGTTGGTGGACCG-3′(HindIII), as reverse primers. The PCR fragment of Ag85B was cloned into the BamHI and SacI site of pET-28a to construct the plasmid pET-28a Ag85B. Subsequently, the fragment of Mpt64190–198-HspX

was generated by PCR from PCR product of HspX as template with the forward primer HspXF2, 5′-ATAGAGCTCTTCGCAGTCACGAACGACGGGGTGATTATGGCCACCACCCTTC-3′(SacI), and the reverse primer HspXR and was cloned into the unique site SacI and HindIII of the previously constructed pET-28a Ag85B plasmid. The correct DNA construct containing the appropriate inserts was confirmed PD98059 by DNA sequencing. Expression and purification of AMH fusion protein.  The plasmid pET-28a AMH was transformed into the Escherichia coli strain BL21 for Compound Library production of the fusion protein AMH. E. coli BL21 expressing AMH was cultured in LB medium for 2 h at 37 °C

before induction with 1 mm isopropylβ-d-thiogalactopyranoside. After induction, growth was continued for 4 h at 37 °C when the bacterial cells were harvested by centrifugation at 12,000 g for 10 min at 4 °C. Then, cells were suspended in buffer A without urea (sodium phosphate buffer 0.1 m, Tris–Cl 0.01 m, pH 8.0) at 5 ml per gram wet weight and sonicated on ice at 200–300 W for 30 min Adenosine triphosphate with 1-s cooling period between each 1-s bursting. The insoluble material containing AMH in inclusion bodies was precipitated by centrifugation at 12,000 g for 10 min at 4 °C, and AMH was solubilized and extracted overnight at 4 °C in buffer B (urea 8 m, sodium phosphate buffer 0.1 m, Tris–Cl 0.01 m, pH 8.0). AMH protein was subsequently purified by Ni-NTA His resin-columns (Merck KGaA, Darmstadt, Germany) according to the manufacturer’s instructions. Fractions containing AMH were identified by 12% SDS-PAGE and pooled. Finally, the pooled fractions were dialysed against urea

concentration gradient (6, 4, 2, 1, 0.5 and 0 m urea with 5 mm Tris–Cl, pH 7.9) for 12 h at each concentration at 4 °C. The concentration of the pure AMH was determined by the Lowry protein assay. Subunit vaccine preparation.  AMM, Ag85B and BCG PSN were prepared as described previously [16]. The preparation of AMH and AMM + AMH vaccines is described below. AMM and AMH were suspended in phosphate-buffered saline (PBS) (0.2 mg/ml), and BCG PSN was suspended in saline (0.6 mg/ml). DDA (Sigma-Aldrich, St. Louis, MO, USA) was suspended in distilled water (2.5 mg/ml), and a homogeneous dispersion of the powder was obtained by heating the suspension to 80 °C for 5–10 min. After cooling at room temperature, the suspension was mixed with diluted AMM, AMH and BCG PSN before use. Vaccination and challenge procedures.

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>